Randomized, Multicenter, Phase II Study of CO-101 Versus Gemcitabine in Patients With Metastatic Pancreatic Ductal Adenocarcinoma: Including a Prospective Evaluation of the Role of hENT1 in Gemcitabine or CO-101 Sensitivity

Gene Expression Levels as Predictive Markers of Outcome in Pancreatic Cancer after Gemcitabine-Based Adjuvant Chemotherapy

(2015) Hayato Fujita et al.   NEOPLASIA

Gemcitabine elaidate

(2014) B. Venugopal et al.   DRUGS OF THE FUTURE

Reporting recommendations for tumor marker prognostic studies (REMARK): explanation and elaboration

(2012) Douglas G Altman et al.   BMC Medicine

Levels of Gemcitabine Transport and Metabolism Proteins Predict Survival Times of Patients Treated With Gemcitabine for Pancreatic Adenocarcinoma

(2012) Raphaël Maréchal et al.   GASTROENTEROLOGY

Combined Analysis of Dihydropyrimidine Dehydrogenase and Human Equilibrative Nucleoside Transporter 1 Expression Predicts Survival of Pancreatic Carcinoma Patients Treated with Adjuvant Gemcitabine Plus S-1 Chemotherapy after Surgical Resection

(2011) Naru Kondo et al.   ANNALS OF SURGICAL ONCOLOGY

Immunohistochemical Analysis of Human Equilibrative Nucleoside Transporter-1 (hENT1) Predicts Survival in Resected Pancreatic Cancer Patients Treated with Adjuvant Gemcitabine Monotherapy

(2011) Soichiro Morinaga et al.   ANNALS OF SURGICAL ONCOLOGY

Metabolism and accumulation of the lipophilic deoxynucleoside analogs elacytarabine and CP-4126

(2011) Auke D. Adema et al.   INVESTIGATIONAL NEW DRUGS

Human equilibrative nucleoside transporter 1 expression is a strong independent prognostic factor in UICC T3-T4 pancreatic cancer patients treated with preoperative gemcitabine-based chemoradiotherapy

(2011) Yasuhiro Murata et al.   Journal of Hepato-Biliary-Pancreatic Sciences

Stromal biology and therapy in pancreatic cancer

(2010) A. Neesse et al.   GUT

Antiproliferative activity, mechanism of action and oral antitumor activity of CP-4126, a fatty acid derivative of gemcitabine, in in vitro and in vivo tumor models

(2010) Andries M. Bergman et al.   INVESTIGATIONAL NEW DRUGS

Human Equilibrative Nucleoside Transporter 1 and Human Concentrative Nucleoside Transporter 3 Predict Survival after Adjuvant Gemcitabine Therapy in Resected Pancreatic Adenocarcinoma

(2009) R. Marechal et al.   CLINICAL CANCER RESEARCH

Consensus Report of the National Cancer Institute Clinical Trials Planning Meeting on Pancreas Cancer Treatment

(2009) Philip A. Philip et al.   JOURNAL OF CLINICAL ONCOLOGY

Significance of RRM1 and ERCC1 expression in resectable pancreatic adenocarcinoma

(2009) H Akita et al.   ONCOGENE

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER

Human Equilibrative Nucleoside Transporter 1 Levels Predict Response to Gemcitabine in Patients With Pancreatic Cancer

(2008) James J. Farrell et al.   GASTROENTEROLOGY

Fluorouracil vs Gemcitabine Chemotherapy Before and After Fluorouracil-Based Chemoradiation Following Resection of Pancreatic Adenocarcinoma

(2008) William F. Regine et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION